F
Ferdinandos Skoulidis
Researcher at University of Texas MD Anderson Cancer Center
Publications - 99
Citations - 7498
Ferdinandos Skoulidis is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & KRAS. The author has an hindex of 24, co-authored 56 publications receiving 3877 citations. Previous affiliations of Ferdinandos Skoulidis include University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis,Michael E. Goldberg,Danielle Greenawalt,Matthew D. Hellmann,Mark M. Awad,Justin F. Gainor,Alexa B. Schrock,Ryan J. Hartmaier,Sally E. Trabucco,Siraj M. Ali,Julia A. Elvin,Gaurav Singal,Jeffrey S. Ross,David Fabrizio,Péter Szabó,Han Chang,Ariella Sasson,Sujaya Srinivasan,Stefan Kirov,Joseph D. Szustakowski,Patrik Vitazka,Robin Edwards,Jose A. Bufill,Neelesh Sharma,Sai-Hong Ignatius Ou,Nir Peled,Nir Peled,David R. Spigel,Hira Rizvi,Elizabeth Jimenez Aguilar,Brett W. Carter,Jeremy J. Erasmus,Darragh Halpenny,Andrew J. Plodkowski,Niamh Long,Mizuki Nishino,Warren Denning,Ana Galan-Cobo,Haifa Hamdi,Taghreed Hirz,Pan Tong,Jing Wang,Jaime Rodriguez-Canales,Pamela Villalobos,Edwin Roger Parra,Neda Kalhor,Lynette M. Sholl,Jennifer L. Sauter,Achim A. Jungbluth,Mari Mino-Kenudson,Roxana Azimi,Yasir Elamin,Jianjun Zhang,Giulia Costanza Leonardi,Fei Jiang,Fei Jiang,Kwok-Kin Wong,J. Jack Lee,Vassiliki A. Papadimitrakopoulou,Ignacio I. Wistuba,Vincent A. Miller,Garrett M. Frampton,Jedd D. Wolchok,Alice T. Shaw,Pasi A. Jänne,Philip J. Stephens,Charles M. Rudin,William J. Geese,Lee A. Albacker,John V. Heymach +69 more
TL;DR: Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets.
Journal ArticleDOI
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
Daniel R. Gomez,Chad Tang,Jianjun Zhang,George R. Blumenschein,Mike Hernandez,J. Jack Lee,Rong Ye,David A. Palma,Alexander V. Louie,D. Ross Camidge,Robert C. Doebele,Ferdinandos Skoulidis,Laurie E. Gaspar,James W. Welsh,Don L. Gibbons,Jose A. Karam,Brian D. Kavanagh,Anne S. Tsao,Boris Sepesi,Stephen G. Swisher,John V. Heymach +20 more
TL;DR: In patients with oligometastatic NSCLC that did not progress after front-line systemic therapy, LCT prolonged PFS and OS relative to MT/O, and the longer-term overall survival (OS) results accompanied by additional secondary end points are presented.
Journal ArticleDOI
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
Daniel R. Gomez,George R. Blumenschein,J. Jack Lee,Mike Hernandez,Rong Ye,D. Ross Camidge,Robert C. Doebele,Ferdinandos Skoulidis,Laurie E. Gaspar,Don L. Gibbons,Jose A. Karam,Brian D. Kavanagh,Chad Tang,Ritsuko Komaki,Alexander V. Louie,David A. Palma,Anne S. Tsao,Boris Sepesi,William N. William,Jianjun Zhang,Qiuling Shi,Xin Shelley Wang,Stephen G. Swisher,John V. Heymach +23 more
TL;DR: Findings imply that aggressive local therapy should be further explored in phase III trials as a standard treatment option in this clinical scenario, and improve PFS relative to maintenance therapy alone.
Journal ArticleDOI
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis,Lauren Averett Byers,Lixia Diao,Vassiliki A. Papadimitrakopoulou,Pan Tong,Julie G. Izzo,Carmen Behrens,Humam Kadara,Edwin Roger Parra,Jaime Rodriguez Canales,Jianjun Zhang,Uma Giri,Jayanthi Gudikote,Maria Angelica Cortez,Chao Yang,You Hong Fan,Michael Peyton,Luc Girard,Kevin R. Coombes,Carlo Toniatti,Timothy P. Heffernan,Murim Choi,Garrett M. Frampton,Vincent A. Miller,John N. Weinstein,Roy S. Herbst,Kwok-Kin Wong,Jianhua Zhang,Padmanee Sharma,Gordon B. Mills,Waun Ki Hong,John D. Minna,James P. Allison,Andrew Futreal,Jing Wang,Ignacio I. Wistuba,John V. Heymach +36 more
TL;DR: Evidence is provided that co-occurring genomic alterations identify subgroups of KRAS-mutant lung adenocarcinoma with distinct biology and therapeutic vulnerabilities, and that KL cells showed increased vulnerability to HSP90-inhibitor therapy.
Journal ArticleDOI
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis,Bob T. Li,Grace K. Dy,Timothy J. Price,Gerald Steven Falchook,Jürgen Wolf,Antoine Italiano,Martin Schuler,Martin Schuler,Hossein Borghaei,Fabrice Barlesi,Terufumi Kato,Alessandra Curioni-Fontecedro,Adrian G. Sacher,Alexander I. Spira,Suresh S. Ramalingam,Toshiaki Takahashi,Benjamin Besse,Abraham Anderson,Agnes Ang,Qui Tran,Omar Mather,H. Henary,Gataree Ngarmchamnanrith,Gregory Friberg,Vamsidhar Velcheti,Ramaswamy Govindan +26 more
TL;DR: Sotorasib showed anticancer activity in patients with KRAS p.G12C-mutated advanced solid tumors in a phase 1 study as discussed by the authors, and particularly promising anti-cancer activity was observed i...